[{"id":"dc0e259c-54c3-443d-979e-3cda462cee90","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634435","created_at":"2021-01-19T20:37:11.137Z","updated_at":"2024-07-02T16:35:38.764Z","phase":"Phase 1","brief_title":"Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients","source_id_and_acronym":"NCT04634435","lead_sponsor":"Biohaven Pharmaceuticals, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e noraramtide (BHV-1100) • CIML NK"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-08-29"}]